Aural Analytics, a privately held digital health company focused on building the world’s most advanced speech analytics platform, today announced a total of $4 in funding. 3 million capital raised in a seed round led by the Morningside Ventures and Tamarisc Ventures venture capital group The round included the participation of Jamie Gates, founding partner and managing director of the Sixth Street Partners Group of TPG, as well as the successful Silicon Valley investor Marc Abramowitz, Arizona Tech Investors (ATI) and Desert Angels. The additional funding secured included a Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF)
“Aural Analytics is the most scientifically sound and technically feasible approach to the use of speech as a method to detect and measure changes in brain health. Aural Analytics is part of the industry’s long sterling history of speech neuroscience,” said Dr. Gerald Chan, co-founder of the Morningside Group; “We believe that the digital Aural Analytics platform will bring about a safe, transparent and far-reaching change in the way we detect, measure and eventually diagnose neurological diseases. We are pleased to support their global expansion and look forward to their progress. “That’s right.
Proceeds from the capital raised will be used to drive the next stage of the company’s growth, which will include further expansion of its clinical trial platform, the global release of its next generation integration portal to support easy speech collection and analytics anywhere in the world, and several new clinical-grade mobile and web-based products to serve the neurology continuum of care. The company also intends to release a series of tool kits for researchers, both internally and externally, that will drive new breakthroughs in speech neuroscience and speech analytics.
“Our company has been built on over 25 years of NIH and NSF-funded research and data across the spectrum of CNS diseases. Since our founding in 2015, we have led speech neuroscience first and successfully launched a transparent, model-driven, clinical-grade analytics suite that is effective in any language, for any disease, anywhere in the world,” said Daniel Jones, co-founder and Chief Executive Officer of Aural Analytics. “This additional capital, along with our extensive industry and research partnerships, has set us on a course that will bring clinically validated, scientifically-driven speech analytics to every corner of the globe. “That’s right.
The tools used in this approach are capable of detecting changes in speech that are imperceptible to trained scientists or clinicians. The Aural Analytics Technology Platform identifies characteristic changes in speech patterns that appear even in the early stages of the disease. The aim of this research line and its commercial applications is the early detection, monitoring and assessment of neurological diseases.
As an example, the company has previously evaluated its metrics for interviews with late champion boxer Muhammad Ali. Aural Analytics’ technology has shown that speech changes related to Parkinsonism have appeared in Ali’s speech years before his formal diagnosis. Similarly, Aural Analytics is prospectively tracking evidence of cognitive-linguistic decline in professional athletes to detect early signs of chronic traumatic encephalopathy.
The non-dilution grant SBIR Phase II of the NSF will be used to further expand the company’s technology and analytical suites. “NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative and effective ideas across all science and engineering markets and areas,” said Andrea Belz, NSF Division Director of Industrial Innovation and Partnerships. “With the support of our research funds, any deep technology start-up or small business can guide basic science in finding meaningful solutions that address enormous needs. “That’s right.
About Morningside Venture
The Morningside Group was founded in 1986 by the Chan family of Hong Kong to invest in private equity and venture capital. Morningside Group is investing in private equity and venture capital opportunities in North America, Europe and Asia Pacific. Morningside Group is investing in the following sectors: manufacturing machinery, high-tech, media, telecommunications, life sciences, education and clean technology. The group is managed by investment professionals who are entrepreneurial, have deep knowledge of the industry and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is deeply committed to social responsibility Access to educational opportunities and support for scientific research are two key areas of focus for Morningside’s philanthropy. For more information, please visit the morning page. Come on,
The National Science Foundation & SBIR
Also known as the American Seed Fund, the NSF SBIR grant awards nearly $190 million annually to start-ups and small businesses, transforming scientific discovery into products and services with commercial and societal impacts. Startups working in almost all fields of science and technology can receive up to $1. $5 million in non-dilution funds to support research and development, helping de-risk technology to achieve commercial success. The US Seed Fund is mandated by the Congress through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of approximately $7. 5 billion to support fundamental research and education in all fields of science and engineering Visit the seed fund for more information Insf Right. Gov
About the Technology Platform for Aural Analytics
Aural Analytics has built a model-driven, transparent analytics engine based on decades of speech neuroscience expertise that has been clinically validated to the highest standard in a number of disease indications. The cloud-based software platform combines beautiful mobile design with speech signal processing and cognitive linguistic analysis into one powerful set of APIs that can be easily extended across the continuum of care. The platform is an agnostic disease, location, language and device and has been deployed in eight languages and four continents. Users can leave samples from anywhere in the world at any time.
The platform uses speech to extract finite but clinically relevant measures by tapping directly into various functions of the nervous system. The first mobile, patient-centric product suite is easy to use, low cost and analytics are available in real-time. The analysis provides insight into key areas known to change with disease, including, but not limited to, motor control, respiratory support and function, and all aspects of cognitive linguistics. Aural Analytics solutions have been widely used in interventional clinical trials, observational research studies and several clinical and consumer settings.
Aural Analytics, Inc.
Aura Analytics, Inc. A privately held digital health company developing the world’s most advanced speech analytics platform, built on the foundation of 25 years of speech neuroscience research and data The company’s technology platform is based on groundbreaking research from Arizona State University and reinforced by a number of high-quality peer-reviewed publications by co-founders Julie Liss, Ph.D. D. D. And, uh, Visar Tobin, Ph D. D. Winners of the 2017 Global SCRIP Award for Best Technology in Clinical Trials, Aural Analytics’ first-of-a-kind technology platform empowers health applications around the world. Company is headquartered in Scottsdale, Ariz Please visit auralanalytics for more information. Come or follow Aural Analytics on Twitter, LinkedIn, Medium and Facebook.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Aural%20Analytics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at firstname.lastname@example.org